The House Energy and Commerce Health Subcommittee today held a hearing on implementation of the Compounding Quality Act, which updated federal requirements for drug compounding facilities after a 2012 fungal meningitis outbreak that was associated with a contaminated compounded steroid medication distributed to patients and providers in 23 states. Witnesses at the hearing included Food and Drug Administration Commissioner Scott Gottlieb, M.D.; officials from two companies that manufacture compounded sterile drugs; a patient; and representatives from the American Academy of Dermatology, International Academy of Compounding Pharmacists, The Pew Charitable Trusts, National Community Pharmacists Association, and American Academy of Ophthalmology. As FDA continues to implement the law, Gottlieb said the agency “plans to take steps that preserve lawful pharmacy practices and expand the opportunities for pharmacies that want to engage in larger-scale compounding to efficiently become 503B facilities.”

Related News Articles

Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
The AHA and Federation of American Hospitals today urged the U.S. Supreme Court to review a federal appeals court decision that allows False Claims Act…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on legislation to roll back changes to the Affordable Care Act by the Trump…
Headline
The AHA yesterday urged Sens. Bill Cassidy, R-La., and Dick Durbin, D-Ill., not to re-introduce legislation that would establish rehabilitation innovation…
Headline
The AHA today expressed support for the Resident Physician Shortage Reduction Act, legislation that would add 15,000 Medicare-funded residency positions over…
Headline
Reps.